Lymphoma Clinical Trials

Showing 1621-1640 of 3,379 trials

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

NCT03704714

This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating participants with diffuse large B-cell lymphoma.

Aggressive Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaCD20 Positive+5 more

Northwestern University30 participantsStarted Nov 2018

Chicago, Illinois, United States • Chicago, Illinois, United States • Lake Forest, Illinois, United States +1 more locations

Active Not RecruitingPhase 1

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

NCT04214886

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.

B-Cell Acute Lymphoblastic Leukemia, AdultB-cell Lymphoma RefractoryB-cell Lymphoma Recurrent

Loyola University24 participantsStarted Dec 2019

Maywood, Illinois, United States

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Related Searches

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

DLBCL Interim Response Evaluation for Customised Therapy

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

A Study of PLX2853 in Advanced Malignancies.

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant